• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Slides for the May 27, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
 
FDA Core Presentations, EGRIFTA (Tesamorelin acetate), NDA 22-505, for the May 27, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee:
 
Dragos Roman, MD, Medical Team Leader Division of Metabolism and Endocrinology Products (DMEP), CDER, FDA (PDF – 54KB)
 
Ali Mohamadi, M.D. Clinical Reviewer DMEP, CDER, FDA (PDF – 516KB)
 
 
Sponsor
 
Theratechnologies, Inc. Core Presentation, EGRIFTA (Tesamorelin acetate), NDA 22-505, for the May 27, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 8.73MB)
 
Theratechnologies, Inc: Backup Slides (PDF – 2.5MB)